Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi.

Abstract

In a prospective, double-blind, placebo-controlled study, the efficacy and safety of acetohydroxamic acid (AHA) in preventing urinary calculogenesis was evaluated in 94 patients with chronic urinary infection. Stone growth occurred in 17% of the AHA group and in 46% of the placebo group (p less than 0.005). Completely reversible side effects consisting predominantly of psychoneurologic and musculo-integumentary symptoms were more prevalent in the AHA group (p less than 0.01). Side effects which were judged 'intolerable' were experienced by 10 (22.2%) of patients in the AHA group and 2 (4.1%) in the placebo group. It is concluded that AHA treatment is effective, relatively safe, and clinically useful in preventing infection-induced urinary calculogenesis.

• Authors: D P Griffith, M J Gleeson, H Lee, R Longuet, E Deman, N Earle
• Journal: European urology (Eur Urol) Vol. 20 Issue 3 Pg. 243-7 ( 1991) ISSN: 0302-2838 [Print] Switzerland
• PMID: 1726639 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Hydroxamic Acids
• Magnesium Compounds
• Phosphates
• Placebos
• acetohydroxamic acid
• Struvite
• Magnesium

Topics

• Adult
• Aged
• Bacteriuria (complications)
• Chronic Disease
• Double-Blind Method
• Female
• Humans
• Hydroxamic Acids (therapeutic use)
• Magnesium
• Magnesium Compounds
• Male
• Middle Aged
• Palliative Care
• Phosphates
• Placebos
• Prospective Studies
• Struvite
• Urinary Calculi (drug therapy, etiology, prevention & control)